Ligand Pharmaceuticals | LGND - Equity Capital And Reserves


Ligand Pharmaceuticals reported $997.32M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Agenus USD -221.22M 49.89M Mar/2026
Amgen USD 9.19B 532M Mar/2026
Anika Therapeutics USD 133.9M 9.56M Mar/2026
Arrowhead Research USD 613.98M 45.56M Mar/2026
Baxter International USD 6.04B 86M Mar/2026
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Eli Lilly USD 31.2B 4.66B Mar/2026
Enanta Pharmaceuticals USD 126.59M 61.87M Dec/2025
Enviri Corporation USD 233.18M 21.88M Mar/2026
Gilead Sciences USD 23.52B 897M Mar/2026
GlaxoSmithKline GBP 17.42B 1.05B Mar/2026
Glaxosmithkline GBP 17.42B 4.64B Mar/2026
Heron Therapeutics USD 9.14M 4.15M Mar/2026
Insmed USD 704.85M 34.12M Mar/2026
Intrexon USD 43.17M 75.33M Jun/2024
Ionis Pharmaceuticals USD 491.41M 2.32M Mar/2026
Karyopharm Therapeutics USD -292.93M 23.67M Dec/2025
Ligand Pharmaceuticals USD 997.32M 19.89M Mar/2026
MacroGenics USD 21.2M 34.39M Mar/2026
Merck USD 45.88B 6.73B Mar/2026
Pacira USD 653.89M 39.22M Mar/2026
Pfizer USD 90.1B 3.63B Mar/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Veracyte USD 1.34B 34.83M Mar/2026